<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143386</url>
  </required_header>
  <id_info>
    <org_study_id>283T10</org_study_id>
    <nct_id>NCT04143386</nct_id>
  </id_info>
  <brief_title>Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease</brief_title>
  <acronym>PREDICTOR</acronym>
  <official_title>Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Estonian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic
      and metabolic abnormalities and very poor long-term prognosis. The prognostic value of
      hemodynamic and metabolic profiling, however, is yet to be determined in this patient group.

      Current study aims to identify novel prognostic biomarkers for better risk stratification of
      late stage LEAD patients. It also allows to determine associations between
      hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances
      (e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury
      biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic
      mechanisms of this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of major adverse cardiovascular events, major adverse limb events and deaths</measure>
    <time_frame>5 years</time_frame>
    <description>A composite of any of the following events, as documented by patients' hospital or death records:
nonfatal myocardial infarction or stroke
fatal myocardial infarction or stroke
hospitalization for angioplasty or bypass surgery for coronary or peripheral vessel disease
LEAD-related major lower extremity amputation
other cardiovascular deaths (cardiac arrest, lethal arrhythmia, heart failure, aortic dissection or rupture)
non-cardiovascular deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of fatal cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-fatal cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of LEAD-related major lower extremity amputations</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for angioplasty or bypass surgery for coronary or peripheral vessel disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths from all causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Lower Extremity Arterial Disease (Fontaine Stages IIb-IV)</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic lower extremity arterial disease referred to Tartu University
        Hospital for revascularization (angioplasty/stenting or bypass surgery).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Fontaine stage I-IIa;

          -  acute limb ischemia;

          -  age &lt;35 or &gt;85 years;

          -  fasting &lt; 6 hours;

          -  time since the last use of tobacco products &lt; 4 hours;

          -  body mass index ≥ 40 kg/m2

          -  blood pressure ≥ 180/120mmHg;

          -  unstable angina;

          -  atrial fibrillation at the time of presentation;

          -  myocardial infarction, stroke or TIA during the preceding 3 months;

          -  any revascularization during the preceding 1 month;

          -  severe heart failure (NYHA IV);

          -  clinically significant heart valve disease;

          -  severe physical disability (other than limb ischemia);

          -  acute infectious disease;

          -  active malignancy or chemotherapy or disease-free &lt; 5 years;

          -  type 1 diabetes;

          -  uncompensated thyrotoxicosis/hypothyroidism or other clinically significant endocrine
             disorders;

          -  moderate to severe asthma (GINA 2016);

          -  severe chronic obstructive pulmonary disease (mMRC grade 3-4)

          -  acute (KDIGO 2012) or chronic renal disease (eGFR-EPI &lt;30mL/min/1.73 m2);

          -  clinically significant acute or chronic liver disease;

          -  severe anemia (&lt;80 g/L);

          -  clinically significant neuroinflammatory or neurodegenerative disease;

          -  active rheumatism;

          -  clinically significant connective tissue disease;

          -  alcoholism or drug abuse;

          -  psychotic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaan Eha, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mihkel Zilmer, dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaido Paapstel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaspar Tootsi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Kuusik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuljo Ööbik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riina Kaur</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <phone>+372 731 8292</phone>
    <email>jaak.kals@kliinikum.ee</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaido Paapstel, MD, PhD</last_name>
    <phone>+372 731 8317</phone>
    <email>kaido.paapstel@kliinikum.ee</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaak Kals, MD, PhD</last_name>
      <phone>+372 731 8292</phone>
      <email>jaak.kals@kliinikum.ee</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <link>
    <url>https://endothelialcentre.ut.ee/</url>
    <description>Endothelial Research Centre</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Jaak Kals</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lower extremity arterial disease</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>metabolism</keyword>
  <keyword>metabolomics</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>biomarkers</keyword>
  <keyword>prognosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

